contact us


Depression is the leading cause of disability worldwide, and is a major contributor to the global burden of disease. Selective serotonin-reuptake inhibitors (SSRIs) are the first line pharmacotherapy in depression but only one third of patients will recover with this treatment. Improved forms of antidepressant treatment are urgently needed. One promising way is to elevate serotonin levels to beyond what SSRIs are capable of, by using adjunctive 5-hydroxytryptophan (5-HTP). 5-HTP is an amino acid that is essential for serotonin biosynthesis in the brain. However 5-HTP makes a poor oral drug because it is rapidly metabolized and has a very short half-life. We aim to overcome this by developing a 5-HTP drug that will provide a steady release of 5-HTP over time; a 5-HTP sustained release (SR) drug.

Project Deliverables

The SR formulations we intend to use are broadly classified as either colon-dependent or colon-independent. Colon absorption of 5-HTP will be compared against upper gastrointestinal absorption to determine which SR formulation would best suit 5-HTP SR drug development.

Principal Investigator: Dr Johnson FAM

Institution: National University Health System

NHIC Ref: NHIC-I2D-1503044



See all BIOPHARMA projects >

SERID™ — A Diagnostic-Therapeutic Device for the Eye

Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are the leading causes of bl...

Development of highly conductive microneedle array for painless dental anaesthesia

Pain management during dental procedures is a cornerstone for successful everyday practice. Curre...

A Rapid Point-of-Care Test Kit for Diagnosing Zika Virus Infection

The Zika virus (ZIKV) is an emerging infectious agent with severe socio-economic impact due to it...

Assay for Early Detection of Flares in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) is an autoimmune condition which affects multiple organ system...

Biomarker for Rapid Diagnosis and Prediction of Severity of Acute Pneumonia

According to the World Health Organization, lower respiratory tract infections are the leading ca...

Towards a Novel Drug Therapy for Treatment-Resistant Depression: Adjunct 5-HTP Slow-Release

Depression is the leading cause of disability worldwide, and is a major contributor to the global...


Clinical Partners

nhg logonuhs logosinghealth


Academic Partners

lkc medicalnus faculty of dentistrynus sphnus somduke nus


Supporting Partners

bms ipodxdipinmrcSCRIseriSMARTEnterpriseSG